Knee pain is a common exercise complaint. Many physical activities can put strain on the knees, causing activity-related joint discomfort, which impairs performance and reduces training gains.
In the recent study from the University of Freiburg, Zdzieblik et al. (2021) investigated the benefits of FORTIGEL®, the specific BCP® (Bioactive Collagen Peptides®) from GELITA, optimized to regenerate cartilage, maintain joint mobility, and minimize joint discomfort.
The study involved 180 physically active young men and women, reporting knee joint discomfort with physical activity, who supplemented with only 5 g of FORTIGEL® or a maltodextrin placebo, for 12 weeks.
The primary outcome from the study showed that supplementation with FORTIGEL® resulted in statistically significant reduction in “pain during activity” compared with the placebo, as assessed by both the study participants and the physician. According to the authors of the study, this “may help to prevent the clinical manifestation of chronic degenerative joint diseases”.
These results confirm the previous findings from Zdzieblik et al. (2017), the first to observe a significant reduction in activity-related joint discomfort from the use of FORTIGEL® compared with placebo, in a RCT involving 139 active men and women.
Dr. Stephan Hausmanns, GELITA’s Vice President for Health & Nutrition, welcomes the new addition to the portfolio of studies: “FORTIGEL® is the most clinically-studied Bioactive Collagen Peptides®, for 30 years. Over 20 studies, involving more than 2,500 participants, contributed to develop FORTIGEL® and prove the product’s positive effects to joint health”, he explains. “So far, no other collagen peptide solution on the market has been able to offer an alternative to FORTIGEL®, backed by science”, concludes Stephan.
Recognizing the uniqueness of the product, Zdzieblik et al. (2021) stated in the study that the effects measured are valid only for FORTIGEL®, the specific BCP® used in the study, and cannot be readily applicable to other collagen products.
Full study: https://www.mdpi.com/2072-6643/13/2/523/pdf
In the recent study from the University of Freiburg, Zdzieblik et al. (2021) investigated the benefits of FORTIGEL®, the specific BCP® (Bioactive Collagen Peptides®) from GELITA, optimized to regenerate cartilage, maintain joint mobility, and minimize joint discomfort.
The study involved 180 physically active young men and women, reporting knee joint discomfort with physical activity, who supplemented with only 5 g of FORTIGEL® or a maltodextrin placebo, for 12 weeks.
The primary outcome from the study showed that supplementation with FORTIGEL® resulted in statistically significant reduction in “pain during activity” compared with the placebo, as assessed by both the study participants and the physician. According to the authors of the study, this “may help to prevent the clinical manifestation of chronic degenerative joint diseases”.
These results confirm the previous findings from Zdzieblik et al. (2017), the first to observe a significant reduction in activity-related joint discomfort from the use of FORTIGEL® compared with placebo, in a RCT involving 139 active men and women.
Dr. Stephan Hausmanns, GELITA’s Vice President for Health & Nutrition, welcomes the new addition to the portfolio of studies: “FORTIGEL® is the most clinically-studied Bioactive Collagen Peptides®, for 30 years. Over 20 studies, involving more than 2,500 participants, contributed to develop FORTIGEL® and prove the product’s positive effects to joint health”, he explains. “So far, no other collagen peptide solution on the market has been able to offer an alternative to FORTIGEL®, backed by science”, concludes Stephan.
Recognizing the uniqueness of the product, Zdzieblik et al. (2021) stated in the study that the effects measured are valid only for FORTIGEL®, the specific BCP® used in the study, and cannot be readily applicable to other collagen products.
Full study: https://www.mdpi.com/2072-6643/13/2/523/pdf
